x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0011738
| Product Information | |
|---|---|
| Clonality | Polyclonal |
| Host Species | Rabbit |
| Reactivity | Human, Mouse, Rat |
| Applications | WB |
| Product Description | Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Leu220 of human Ambra1 protein. Antibodies are purified by protein A and peptide affinity chromatography. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | AMBRA1 |
| UniProt No. | Q9C0C7 |
| Gene ID | 55626 |
| Gene Description | Activating molecule in Beclin1-regulated autophagy is a WD40-containing protein expressed during neurodevelopment that is required for neural tube development and autophagy. Several studies have identified interactions between Ambra1 with regulators of autophagy and apoptosis. Ambra1 was originally found to interact with Beclin-1, a key protein responsible for activating the class III PI3K Vps34. Further studies showed that Ambra1 tethers the Beclin-1-Vps34 complex to the cytoskeletal network through dynein light chains and that during autophagy ULK1 phosphorylates Ambra1, resulting in disassociation with dynein and translocation of the Beclin-Vps34 complex to the endoplasmic reticulum to initiate autophagosome formation. In addition, it has been found that Ambra1 binds to mitochondrial Bcl-2 and that this interaction is regulated by either apoptosis or autophagy. Ambra1 also interacts with Parkin, an E3 ubiquitin ligase important for mitophagy, a selective autophagic process of mitochondrial clearance. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
